Plant Name: Illicium difengpi
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.287E-11 | 4.980E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.512E-10 | 8.178E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.894E-09 | 2.139E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.642E-08 | 7.149E-05 | ALOX12, ALOX15, CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.760E-07 | 2.395E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.203E-07 | 2.822E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.222E-07 | 3.692E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 3.461E-07 | 3.769E-04 | AKR1B10, CYP1A2, CYP2C19, CYP2C9, CYP3A4, NR1H4 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.356E-06 | 1.094E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.356E-06 | 1.094E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.934E-06 | 1.504E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 4.066E-06 | 2.606E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 4.066E-06 | 2.606E-03 | CNR1, CNR2 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.066E-06 | 2.606E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.066E-06 | 2.606E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 4.066E-06 | 2.606E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 8.126E-06 | 4.782E-03 | CNR1, CNR2 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 9.344E-06 | 4.787E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 8.614E-06 | 4.787E-03 | CYP2C19, CYP2C9, CYP3A4 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 9.673E-06 | 4.787E-03 | CNR2, MAPK1, SMN1, SMN2 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.353E-05 | 6.406E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.477E-05 | 6.845E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.472E-10 | 1.958E-08 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.563E-07 | 1.039E-05 | CYP2C9; ALOX15; MAPK1; ALOX12; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 7.092E-07 | 3.144E-05 | CYP2C9; ALOX15; ALOX12; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.093E-06 | 3.635E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.828E-06 | 1.070E-04 | CYP2C9; AKR1B10; FASN; IDH1; CYP1A2; ALOX15; ALOX12; CYP2C19; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.190E-06 | 5.825E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.066E-05 | 1.008E-03 | IDH1; MAPK1; TP53 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.539E-05 | 1.008E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.840E-05 | 1.159E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 5.365E-04 | 6.487E-03 | LMNA; MAPK1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.040E-04 | 6.487E-03 | MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.876E-03 | 1.782E-02 | MAPK1; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.620E-03 | 1.657E-02 | MAPK1; TP53 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.009E-03 | 1.119E-02 | MAPK1; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.518E-03 | 1.902E-02 | MAPK1; TP53 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.004E-03 | 1.902E-02 | MAPK1; MAPT; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.294E-03 | 1.902E-02 | MAPK1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.595E-03 | 1.902E-02 | MAPK1; TP53 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.996E-03 | 1.902E-02 | MAPK1; TP53 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.791E-03 | 2.192E-02 | CNR2; CNR1; TSHR |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.011E-03 | 1.783E-02 | CYP1A2; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.164E-03 | 1.913E-02 | MAPK1; TP53 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.662E-03 | 2.583E-02 | MAPK1; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.996E-03 | 1.902E-02 | NR1H4; CYP3A4 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 5.962E-03 | 3.050E-02 | CNR1; MAPK1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.053E-03 | 3.815E-02 | MAPK1; TP53 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 8.318E-03 | 3.815E-02 | MAPK1; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 8.318E-03 | 3.815E-02 | MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.013E-02 | 4.493E-02 | MAPK1; TP53 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.103E-02 | 4.731E-02 | FASN; MAPK1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.737E-03 | 3.050E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | FASN |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | CNR1; CNR1; GPBAR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | CNR1; CNR1; CNR1; CNR1; CNR1; CNR1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | CNR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| A00-B99: Certain infectious and parasitic diseases | Mycobacterium tuberculosis infection | A15-A19 | FASN |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | CNR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR1; CNR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | CNR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; MAPK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CNR1; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | CNR1; CNR1; CNR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | FASN |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; FASN; MAPK1 |
| NA: NA | Gram-positive bacterial infection | NA | FASN |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR1; CNR2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CNR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | CNR1; GPBAR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | CNR1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; IDH1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dramatic weight loss | R63.4 | FASN |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CNR1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |